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Objectives
To better understand the influence of prostate-specific antigen (PSA) screening and other health system determinants on prognosis of prostate cancer, up-to-date relative survival (RS), stage distributions, and trends in survival and incidence in Germany were evaluated and compared with the United States of America (USA).
Patients and Methods
Incidence and mortality rates for Germany and the USA for the period 1999-2010 were obtained from the Centre for Cancer Registry Data at the Robert Koch Institute and the USA Surveillance Epidemiology and End Results (SEER) database. For analyses on stage and survival, data from 12 population-based cancer registries in Germany and from the SEER-13 database were analysed. Patients (aged ≥ 15 years) diagnosed with prostate cancer (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) and mortality follow-up to December 2010 were included. The 5-and 10-year RS and survival trends (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were calculated using standard and model-based period analysis.
Introduction
Prostate cancer is the most frequent cancer and the third leading cause of cancer death among men in Germany, with 70,000 new cases expected in 2016 [1] . Prostate cancer incidence varies widely around the world, with by far the highest rates in the USA [2] . In the USA, PSA testing was implemented in 1986. This implementation resulted in a rapid increase in prostate cancer incidence. In the USA, in 2001, 57% of the male population aged > 50 years had had a PSA test [3] . The USA Preventive Services Task Force has recommended against PSA-based screening regardless of age since 2012 [4] . In Germany and other European countries, PSA testing was implemented later and increased in the 1990s [5] . The German Health Interview and Examination Survey (2008) (2009) (2010) (2011) reported that 30.6% of men aged > 45 years had had a PSA test [6] . However, in the German healthcare system, PSA screening has never been generally recommended and PSA testing is not covered by the statutory health insurance.
The influences of healthcare practices, such as PSA screening, on the population level can be explored using populationbased cancer registry data by comparing incidence, mortality, and survival trends over time and differences across countries. The differences in PSA implementation between Germany and the USA, together with the availability of welldocumented population-based cancer registry data in both countries [7, 8] , allow for such comparisons for prostate cancer between these two countries in particular.
The aim of the present study was to provide the first comprehensive comparison of prostate cancer incidence, mortality, and relative survival (RS) in Germany and the USA, including an assessment of trends and stage-specific associations.
We hypothesised, that the comparison between these two countries could clarify the implications of PSA screening utilisation on tumour stage at presentation and survival. Specifically, we hypothesised higher proportions of earlier tumour stages and better survival in the USA.
Patients and Methods

Databases -Incidence and Mortality
Prostate cancer incidence and mortality rates for Germany in 1999-2010 were described using data from the Centre for Cancer Registry Data at the Robert Koch Institute [9] . For regions with high completeness, the observed incidence was directly used, while for regions with insufficient data quality, completeness-corrected incidence rates were calculated. Mortality information derived from the official cause of deaths statistics covered the entire German population.
For the USA, incidence rates in 1999-2010 were extracted from the Surveillance Epidemiology and End Results (SEER)-13 database [8] . The SEER-13 database was chosen, as it contains all years relevant to our analyses. It includes data from 13 regional cancer registries throughout the USA that are chosen for their high quality and epidemiologically significant population. The database covers 41.3 million inhabitants (13% of the total USA population). While the population of the SEER registries is similar to the general USA population in most respects, there is a deliberate oversampling of some minority ethnic groups and a higher proportion of foreign-born persons [10, 11] . Furthermore, it has been suggested that survival might be slightly higher in the SEER regions than in the general population [12] .
Mortality rates for the same period were extracted from the SEER*Stat database covering the entire USA population.
Databases -Stage Distribution and Survival
Analyses on stage distributions and prostate cancer survival in Germany were based on a pooled national German cancer registry dataset [7] . Data sources and quality control checks have been described previously [7] . The dataset comprises data from 12 population-based cancer registries encompassing 12 of the 16 federal states and covering 26.7 million inhabitants (33% of the total German population). As two cancer registries did not provide data for the entire study period, they were excluded in the trend analysis. In general, patients (aged ≥ 15 years) diagnosed with primary malignant tumours (1997-2010) and mortality follow-up to December 2010 were included. Here, we focus on prostate cancer [International Classification of Diseases (ICD)-10 code C61]. Cases registered based on death certificate only (DCO) information (5.4% in 2007-2010) and carcinoma in situ (CIS) cases were excluded.
For comparative analysis, patients with prostate cancer in the USA with the same inclusion and exclusion criteria as in Germany were selected from the SEER-13 database [8] .
Statistical Analysis -Incidence and Mortality
Trends for overall incidence and mortality were described by reporting age-standardised rates per 100,000 (agestandardised using the 2000 world standard population [13] ) at the beginning and at the end of the study period and by graphical representation of overall and age-specific (45-54, 55-64, 65-74, ≥75 years) incidence and mortality rates by year of diagnosis.
Statistical Analysis -Stage Distribution and Survival
To examine survival by stage, tumours were grouped into localised, regional, distant, and unknown stages. Stage for patients in Germany was built by transforming TNM information: localised (T1/2N0M0), regional (T3/4N0M0 or any TN+M0), and distant (any T any NM+) [14] . A comparable stage classification for the USA data was derived using the summary staging 2000 [15] . As this stage variable was only available for 1998 and later, comparative stage based analyses were restricted to the period 1998-2010 for USA patients. Patients with missing information on stage were excluded from the main analyses (Germany, 54%; USA, 4%) to have a comparable patient sample before and after stage adjustments in the analyses. Differences in stage distribution by period (1998-2000, 2001-2003, 2004-2006, and 2007-2010) in Germany and in the USA were examined and tested for significance using chi-square tests.
RS was estimated by period analysis [16] . Period analysis has been shown to provide more up-to-date survival estimates than traditional cohort analysis. In cohort analysis, a cohort of patients diagnosed in a number of calendar years in the past is followed over years and survival cannot be obtained until a complete follow-up (e.g. 5 years for 5-year survival) is available for all included calendar years. In period analysis, the survival analysis is restricted to some recent calendar period by left truncation of survival times at the beginning of the period of interest, in addition to right censoring at its end. It has been shown that period analysis closely predicts the survival observed later for patients diagnosed in the period of interest [17] . RS was calculated as the ratio of the observed survival in the group of patients with prostate cancer divided by the expected survival of a comparable group in the general population [18] . Expected survival was derived according to the Ederer II method [19] from life tables, stratified by age, sex, calendar year, and in the USA race (White/Black), as obtained from the German Federal Statistical Office [20] and the Centers for Disease Control and Prevention [21] in the USA.
For country comparisons, the 5-and 10-year age-standardised RS and RS by stage and by age (for 5-year RS: 15-54, 55-64, 65-74, 75-84, and ≥85 years; for 10-year RS the last two groups were collapsed) were calculated for the period 2007-2010. This period 2007-2010 was chosen for analysis, as the survival estimates for 2007-2010 are the most up-to-date survival estimates that can be derived from the given datasets. The start of the period was set to 2007, as the database started with the year of diagnosis 1997 and, thus, all available diagnosis years were included in the analyses on 10-year RS resulting in the best possible power. Age-standardisation was conducted according to International Cancer Survival Standards proposed by Corazziari et al. [22] . Model-based period analysis [23] was used to test for differences in RS in 2007-2010 across countries after adjustment/stratification for age or for age and stage. In model-based analysis, the numbers of deaths were modelled as a function of the year of follow-up, age (in age-standardised analysis), stage (in stageadjusted analysis), and country, by Poisson regression with the logarithm of the person-years at risk as offset. In consideration of the large proportion of patients with missing stage information in the German dataset, firstly we provide the analysis only for patients with prostate cancer with known stage and secondly for patients with and without known stage. All calculations were performed with SAS statistical software package (version 9.1, SAS Institute INC., Cary, NC, USA), using macros for period [24] and model-based period analysis [23] .
Results
Datasets
The basic characteristics of the German and USA dataset are presented in Table 1 . From a total of 233 823 patients in the German dataset, 19 057 cases notified by DCO or autopsy only and 25 CIS cases were excluded, leaving a total of 214 741 patients with prostate cancer. The median age was 67 years at diagnosis in Germany. For the USA, from a total of 382 171 patients, 2999 cases notified by DCO and one CIS case were excluded, leaving a total of 379 171 patients with prostate cancer (median age, 67 years; 77.7% White, 12.9% Black, 9.4% Other). Patients with missing information on stage were excluded in stage-specific analysis (Germany, 54%; USA, after restricting to diagnosis years 1998-2010, 4%) leaving 98 965 patients in Germany and 342 307 in the USA.
Incidence Trends
In Germany, overall incidence of prostate cancer increased during the observation period from 56.0 per 100,000 in 1999 to 76.0 per 100,000 in 2010, with largest increases among patients aged 65-74 years (Fig. 1A) . For men aged ≥75 years, prostate cancer incidence decreased strongly over time. By contrast, in the USA overall prostate cancer incidence steadily decreased from 118.6 per 100,000 in 1999 to 99.8 per 100,000 in 2010, with the largest decreases among patients aged ≥65 years (Fig. 1B) .
Trends in stage distribution
The stage distribution of prostate cancer cases changed significantly between 1998 and 2010 in both countries 552 © 2016 The Authors BJU International © 2016 BJU International (P < 0.001; Fig. 2 ). In Germany, the proportion of localised cases increased from 51.7% (4513 cases) in 1998-2000 to 67.5% (18 618 cases) in 2007-2010, while in the USA only small changes were seen in the distribution of cases by stage. In contrast to Germany, a large proportion of localised cases were already observed in 1998-2000 (80.5%).
Mortality rates
Overall, prostate cancer mortality slightly declined from 14.6 per 100,000 in 1999 to 11.4 per 100,000 in 2010 in Germany (Fig. 1C) and from 13.6 per 100,000 in 1999 to 9.5 per 100,000 in 2010 in the USA (Fig. 1D) . Declines in mortality were especially large among men aged ≥ 75 years in both countries.
Prostate Cancer Survival by Country
Prostate cancer survival in German patients was significantly lower than the survival in USA patients (P < 0.001; Table 2 ), with 5-and 10-year overall age-standardised RS of 93.3% and 90.7% in Germany and 99.4% and 99.6% in the USA, in 2007-2010. Significant differences in 5-year RS between countries were seen for all age groups, with largest differences among patients aged 75-84 and ≥85 years (10.1% units (P = 0.002) and 13.3% units (P = 0.047) higher RS in the USA, respectively). Differences in 10-year RS were largest for patients aged 15-54 and ≥75 years, at 15.4% units (P < 0.001) and 11.4% units (P = 0.002), respectively. By contrast, stage-specific differences in survival between countries were small, and age-specific differences mostly lost statistical significance after adjustment for stage despite the large sample size of both datasets (with the exception of 5-and 10-year RS among patients in age groups 15-54 and 55-64 years, where small differences were still significant; both P < 0.001). Whereas both 5-and 10-year age-standardised RS were slightly >100% among patients with localised cancer (indicating lower mortality compared to the general population of the same age) and only slightly <100% for patients with regional cancer spread in both countries, prognosis was poor with 5-and 10-year RS close to 30% and <20% respectively for patients with distant cancer.
When including patients with missing stage information in survival analyses, 5-and 10-year RS estimates decreased by 0-5% units (Table S1) , with the strongest changes for elderly patients. 
Survival Trend Analysis
Discussion
This is the first study providing a detailed comparison of prostate cancer incidence, mortality, and RS in Germany and the USA. Our present results show strong major differences in prostate cancer incidence trends, stage distributions, and survival across countries. However, survival differences across countries and over time were largely explained by differences in stage distributions.
Differences in Stage and its Relationship to PSA Screening
The present study showed a significant and large change in the stage distribution from regional and distant to localised stage from 1998-2000 to 2007-2010 in Germany. Similarly, a comparable shift from capsule-exceeding to capsule-limited tumours was shown in an analysis of data from the Munich Cancer Registry [5] . Comparable changes in stage distribution could be shown for other European countries too [25] . In contrast, in the USA, the proportion of localised stages was in 1998-2000 already higher than the proportion in Germany in 2007-2010 and no consistent changes over time were found. The already high incidence of prostate cancer seen in the USA in our present and previous studies [26, 27] , and the ever increasing incidence seen in Germany are likely to reflect the earlier introduction and more widespread use of PSA testing in the USA [26, 28] , as well as increasing application in Germany in later years [5] , which does go along with a shift towards earlier diagnoses or localised tumour stage. However, the use of PSA testing in Germany is still far below the rates of the USA [3, 6] . There are several possible reasons for this circumstance. In contrast to the USA, PSA screening has never been generally recommended in Germany. The PSA test is an individual out-of-pocket health service among people who have statutory health insurance or partly paid by Overall age-standardised and age group-specific prostate cancer incidence in Germany
Overall age-standardised and age group-specific prostate cancer incidence in the USA Overall age-standardised and age group-specific prostate cancer mortality in Germany
Overall age-standardised and age group-specific prostate cancer mortality in the USA private insurances. For this reason, there are no more detailed data (e.g. insurance data) about the use of PSA testing in Germany beyond the results of the survey mentioned above [6] .
Changes in Survival Rates
In our present study, we found significant increases in overall and age-specific prostate cancer survival between 2002 and Staging beginning from 1998 in the USA; ‡ differences of RS between Germany and the USA based on period estimates; § differences of RS between Germany and the USA based period on stage-adjustment period estimates (here, the stage distribution of the pooled German and USA dataset was used); SE, standard error; P, P value from the model-based period analysis comparison; na, not applicable.
© 2016 The Authors BJU International © 2016 BJU International 555 2010 in Germany and only modest to no increases in the USA. Recent reports in prostate cancer survival in the USA and in Europe have shown dramatic increases in survival for this cancer during the last two decades [26, 27] . A comprehensive study that included data from patients with prostate cancer from 12 European countries (including Germany and the USA) reported significant increases in 5-year RS estimates, between the periods 1990-1994 and 2002-2006 [26] . In that study, survival for German patients (restricted to the Saarland registry), significantly increased among those aged 40-64, 65-74, and ≥75 years (15.9%, 11.0%, and 19.4% units of difference in RS between the studied periods, respectively), while USA patients presented the lowest increases in survival, with 9.8%, 8.0% and 5.8% units, respectively, but already had high survival in the first period. However, in our present analysis, survival increases were no longer present after accounting for changes in disease stage. Furthermore, stage-specific survival did not increase in our present study between 1997 and 2010 and in the Munich study between 1990 and 2010 [5] . These observations, along with the increase in incidence in Germany, most likely reflect the effects of increasing opportunistic screening for prostate cancer among asymptomatic men [28] , in which over-diagnosis of indolent and slow growing tumours leads to overtreatment with no real gain in survival over time.
More specifically, our present analysis strongly suggests that PSA testing became much more common in Germany throughout the 1990s and lagged USA practice by~10 years. As a result, many more men were diagnosed with localised prostate cancer much earlier in the time course of the disease, leading to stage shift because cancer is found earlier in its natural history. The increased lead time 'improves' 5-and 10-year survival, but may or may not improve overall survival. This could explain why we found only modest changes in mortality rates.
Differences Between the Countries
Additionally, we found that major differences in prostate cancer survival between Germany and the USA were mainly due to differences in the stage of the disease, although slight differences in RS in patients aged 15-64 years between the two countries remained significant after stage-adjustment. Age-standardised RS in 2007-2010 was close to 100% for patients with localised and regional tumour spread in both countries. Conversely, 5-and 10-year RS of patients with metastatic disease remained low with close to 30% and <20% in both countries. In this context, it should be noted that this refers to data before the advent of the new systemic treatment options or strategies (e.g. chemotherapy in hormone-sensitive prostate cancer). Whether these options might improve survival remains to be seen.
Results from the comparison of mortality rates in Germany and the USA showed that in relation to the enormous Table 3 Model-based 5-year RS trends for patients with prostate cancer by age group, stage, and overall, in Germany* and in the USA. Poisson model did not converge; SE, standard error of point estimate; Diff., difference between the last and first period; P, P value for the model-based period analysis comparison; na, not applicable.
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© 2016 The Authors BJU International © 2016 BJU International therapeutic efforts implemented during the study period, the overall decline in mortality was comparatively small. For example, a doubling of curative therapy for prostate cancer has been reported in the USA [29] . In the dataset of the Munich Cancer Registry, the proportion of radical prostatectomy increased continuously between 1990 and 2010 from 20% to almost 50%, whereas hormone therapy decreased from 55% to 18% [5] . Also, the use of hormone therapy in conjunction with primary radiation therapy increased significantly during the 1990s. To what extent the increase in opportunistic PSA screening in Germany may have contributed to the decline in prostate cancer mortality is uncertain. Some studies like the G€ oteborg randomised screening trial suggested a strong impact of organised PSA screening on prostate cancer mortality [30] . Still the question as to which proportion of the falling mortality rate is attributable to PSA testing remains difficult to answer given that dropping mortality rates in other countries with relatively low use of PSA screening support the impact of non-screening related factors as well [31] . In many European countries, mortality from prostate cancer started to decline well before the spread of PSA testing. In the USA, model projections showed that 45-70% of the observed decline in prostate cancer mortality during the 1990s could be explained by stage shift created by PSA screening [32] .
When comparing data from the USA and Germany, it has to be considered that the healthcare systems of Germany and the USA differ in insurance coverage and the access to health services. It was estimated that in 2012, 17.9% of the USA population aged <65 years did not have health insurance. Most persons aged ≥65 years are eligible for Medicare and, thus, the number of uninsured person was estimated to be lower (1.7%) in this age group [33] . In Germany, having a health insurance is mandatory. Only 0.2% of the German population has neither a public or statutory health insurance [34] . As the analysed databases do not include data on socioeconomic status, race (only available in the USA), or insurance status (only available in the US starting in 2007), these factors could not be considered in the analyses. However, several other studies identified variability in prostate cancer stage, treatment, and survival based on insurance status, income, and geographical region [35] [36] [37] .
Disparity in access to cancer care or resulting disparities in (prostate) cancer outcomes in Germany have rarely been analysed. On the one hand, it must be assumed that countries with a public healthcare system, such as Germany, might have less disparity in pattern and quality of care or inequalities in cancer mortality. Mackenbach et al. [38] showed that the resource inequalities are relatively small in European Nordic countries and continental Europe. On the other hand, offering and use of out-of-pocket healthcare services (e.g. PSA testing) are more frequently in patients with higher income [39, 40] . Furthermore, screening rates for breast, prostate, skin, and colorectal cancers are significantly higher in areas with higher physician density [41] . However, results on area-based socioeconomic deprivation and prostate cancer survival in Germany have shown only marginal associations compared to the disparities reported in the USA [42] . Thus, differences in healthcare systems might explain some of the reported differences between Germany and the USA.
A major strength of the present study is the large sample size, the use of period analysis to report detailed and most up-todate survival estimates and trends, and the incorporation of stage information in the country comparison and trend analysis. For the first time in the PSA screening era, it was possible to carry out an extensive comparison of survival data between Germany and the USA.
A main limitation of our present study is the large proportion of patients with missing stage information in the German dataset. The proportion of patients with missing stage information was~58% between 1997 and 2004 and decreased to~47% in 2010. Patients with missing stage information were older and had a slightly lower 5-year age-adjusted RS (89.2% vs 93.3%). Thus, excluding these patients might have led to an overestimation of survival in Germany. If this was the case, then the survival gap between Germany and the USA would even be wider. However, when repeating the analysis using only data from two registries with the lowest proportion of patients with missing stage [Brandenburg (33%), Th€ uringen (43%)], survival estimates were generally comparable (data not shown).
Another limitation of our present study is the relatively high DCO proportion in the German dataset. As DCO cases can be expected to have shorter survival times, the exclusion of these cases might lead to slight overestimations of survival [43] . However, the high proportions of DCOs in the German dataset may also be partly due to the fact that many of the cancer registries are still rather young and some proportion of the DCOs may simply be cases who had not been known to the registries as their diagnosis was made prior to the registration period [44] .
Furthermore, the life table methods used for estimating RS assume that censoring of patients is independent from their risk of death and that the probability of death is constant within the time intervals [45] , which may have led to some minor imprecisions of survival estimates in our present analysis, which used 1-year time intervals.
Another limitation is the lack of information on comorbidities and initial treatment. Therefore, different treatment patterns between the USA and Germany (e.g. a much higher relative use of radiotherapy for low-risk prostate cancer in the USA [46] ) were not taken into account.
In conclusion, the survival increases in Germany between 2002-2004 and 2008-2010 , and the survival advantage in the USA are mostly explained by differences in incidence and stage distributions over time and across countries. Effects of early detection and over-diagnosis or a lead-time bias due to the more widespread utilisation and the earlier introduction of PSA testing in the USA should be considered. Persistent poor survival for metastatic prostate cancer in Germany and the USA should stimulate a review of the current care and management of patients with prostate cancer in general and especially for metastatic disease. The recent options of medical treatment and new multimodal therapeutic strategies can possibly contribute to a better survival in such cases.
